Assembly Biosciences, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Assembly is a clinical-stage biotechnology company developing therapies for viral diseases. It has no approved products and has not generated product-sales revenue. Financial amounts below are in U.S. dollars; millions unless noted.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior balance-sheet date |
|---|---|---|
| Collaboration revenue | $5.8 million | None |
| Research and development expense | $11.9 million | $14.5 million |
| General and administrative expense | $4.6 million | $5.0 million |
| Operating loss | $10.7 million | $19.6 million |
| Net loss | $9.1 million | $19.0 million |
| Basic and diluted loss per share | $1.66 | $4.46 |
| Net cash used in operating activities | $18.4 million | $23.4 million |
| Cash and cash equivalents | $18.7 million | $19.8 million at December 31, 2023 |
| Marketable securities | $94.2 million | $110.4 million at December 31, 2023 |
| Total assets | $119.9 million | $136.8 million at December 31, 2023 |
| Total liabilities | $87.3 million | $95.7 million at December 31, 2023 |
| Stockholders’ equity | $32.6 million | $41.1 million at December 31, 2023 |
Revenue was recognized under the Gilead collaboration; the company reported no product-sales revenue. Gross margin is not a meaningful disclosed measure for this development-stage business. The balance sheet reports no borrowings; liabilities primarily include deferred collaboration revenue, accrued expenses, and lease obligations. Cash, cash equivalents, and marketable securities totaled approximately $113.0 million at quarter-end.
Changes versus the prior comparable period
- Collaboration revenue increased from zero to $5.8 million, reflecting services performed under the Gilead agreement.
- Net loss narrowed by $9.9 million. Lower R&D expense, partly reflecting discontinuation of ABI-H3733 and vebicorvir programs, and higher interest income contributed to the improvement.
- R&D expense decreased 18% to $11.9 million; G&A expense decreased 8% to $4.6 million. Spending on newer programs, including ABI-1179 and ABI-6250, partly offset reductions elsewhere.
- Operating cash use declined by $5.1 million year over year. Cash and cash equivalents fell by $1.1 million during the quarter, while marketable securities declined as securities matured and funds were redeployed.
- The company implemented a 1-for-12 reverse stock split in February 2024 and regained Nasdaq’s minimum-bid-price compliance. Prior share and per-share figures were retrospectively adjusted.
Outlook, collaboration, and risks
- Management expects existing cash, cash equivalents, and marketable securities to fund operating expenses and capital requirements into the second half of 2025. The notes separately state management believes funds are sufficient for at least 12 months after issuance of the financial statements.
- Management expects four programs to initiate clinical studies in 2024: ABI-5366 and ABI-4334 by midyear, followed by ABI-6250 and Gilead-contributed ABI-1179 by year-end. The filing reports that CTAs for ABI-5366 and ABI-4334 were approved in April 2024, after quarter-end. Interim ABI-5366 Phase 1a data was expected in Q3 2024 and Phase 1b data in the first half of 2025.
- The Gilead collaboration provided $100.0 million in total proceeds in 2023, comprising an $84.8 million upfront collaboration payment and a $15.2 million equity investment. Gilead held 19.9% of outstanding voting shares at March 31, 2024 and has program opt-in rights, potential additional equity-purchase rights, and two board designees.
- At March 31, deferred Gilead collaboration revenue was $80.5 million ($32.8 million short-term and $47.7 million long-term). The agreement includes potential opt-in fees of $45 million to $125 million per program, up to $330 million in milestones per opted-in program, and tiered royalties; these are contingent and not assured proceeds.
- Management expects expenses to rise as programs advance. The company anticipates needing additional capital over time; equity financing could dilute shareholders, and financing may not be available on acceptable terms. Failure to secure funds could require delaying, reducing, or discontinuing development.
- Key risks include clinical, safety, regulatory, manufacturing, and trial-enrollment uncertainty; reliance on CROs and other third parties; dependence on Gilead and the possibility it does not opt in or terminates; and competition, intellectual-property, and market-financing risks. The company reported no material legal proceedings and no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether the planned 2024 trial starts and anticipated ABI-5366 data milestones occurred, and what subsequent safety and efficacy data show.
- Actual quarterly cash burn and whether the stated runway remains consistent with development spending and any new financing.
- Gilead’s future program opt-in decisions, collaboration performance, and any additional equity purchases or resulting dilution.
- Whether the decrease in reported losses reflects sustainable expense levels or timing, discontinued programs, and noncash or collaboration-accounting effects.
- The effects of the reverse split and subsequent share issuance on per-share comparisons and ownership.